Monday June 26th 2017

Archive for December, 2013

Identifying the Start of Multiple Sclerosis Injury: A Serial DTI Study

Identifying the Start of Multiple Sclerosis Injury: A Serial DTI Study

CONCLUSIONA significant change in diffusion measures can be seen prior to gadolinium enhancement. Changes in TD drove changes in FA and MD, providing evidence for impaired myelin integrity prior to gadolinium enhancement. DTI may be a sensitive measure for early detection [Read More]

Overlapping demyelinating syndromes and anti‐NMDA receptor encephalitis

Overlapping demyelinating syndromes and anti‐NMDA receptor encephalitis

Abstract Objective: To report the clinical, radiological, and immunological association of demyelinating disorders with anti‐N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis. Methods: Clinical and radiological analysis of a cohort of 691 patients with anti‐NMDAR [Read More]

American Academy of Neurology Guideline Addresses Emotional Disorders in Individuals with MS

American Academy of Neurology Guideline Addresses Emotional Disorders in Individuals with MS

American Academy of Neurology Guideline Addresses Emotional Disorders in Individuals with MS. [Read More]

 Page 1 of 86  1  2  3  4  5 » ...  Last » 

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]